What is it about?
Osteosarcoma is the most frequent primary bone tumor in the pediatric age group. Its aggressive local growth pattern and its high propensity to metastasize, mainly to the lungs, give the disease an unfavorable prognosis that has situated this disease as one of the leading causes of pediatric cancer death. Current protocols for osteosarcoma treatment are based on neo-adjuvant (pre-operatory) chemotherapy followed by surgical resection of the tumor and a new phase of adjuvant chemotherapy. Despite the progress that these protocols have made in improving the outcome of the disease, the limited access of drugs to bone tumor and metastases, their indiscriminate distribution in the organism, the high required doses that cause intolerable toxicity and the development of multidrug resistance, still represent a major challenge. Nanotechnology has emerged as a new strategy to successfully address these problems by the development of nanoscaled drug carriers that present the ability to target the drug to the tumor cells, achieving high drug concentrations in the tumor area, while decreasing its presence in healthy tissues and therefore its potential systemic toxicity. This review summarizes the different lipid nanocarriers developed to deliver first and second-line anti-osteosarcoma drugs as well as emerging agents in the treatment of this disease. Moreover, it also discusses the potential of these nanocarriers for the treatment of osteosarcoma.
Why is it important?
Biodegradable and biocompatible LN constitute an attractive and promising platform to passively or actively direct the antitumor agents to the desired site of action, increasing their bioavailability in the primary and metastatic tumor sites while decreasing the systemic toxicity associated to their use. Moreover, LN can be orally administered avoiding the intravenous route, and can thus improve OS patients’ welfare.
Read the Original
This page is a summary of: Antitumoral-Lipid-Based Nanoparticles: a Platform for Future Application in Osteosarcoma therapy, Current Pharmaceutical Design, December 2015, Bentham Science Publishers, DOI: 10.2174/1381612821666151027152534.
You can read the full text:
The following have contributed to this page